Voyager Therapeutics to Present Second Quarter 2022 Results and Corporate Update

CAMBRIDGE, Mass., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a gene therapy and neuroscience company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, will report second quarter 2022 financial and operating results after market close on Thursday, August 4, 2022. Subsequently, the Company will host a live conference call and webcast at 4:30 p.m. ET to discuss its financial and operating results and provide a corporate update.

The conference call may be accessed by dialing 1-833-634-2276 (domestic) or 1-412-902-4144 (international) and asking for the Voyager Therapeutics earnings call. A live webcast of the call will also be available on the Investors section of the Voyager website at ir.voyagertherapeutics.com, and a replay will be available at the same link after its completion. The replay will be available for at least 30 days following the conclusion of the call

About Voyager Therapeutics
Voyager Therapeutics (Nasdaq: VYGR) is leading the next generation of AAV gene therapy to unlock the potential of the modality to treat devastating diseases. Proprietary capsids born from the Voyager’s TRACER™ capsid discovery platform are powering a rich early-stage pipeline of programs and may elevate the field to overcome the narrow therapeutic window associated with conventional gene therapy vectors across neurologic disorders and other therapeutic areas.
voyagertherapeutics.com       LinkedIn       Twitter 

Voyager Therapeutics^® is a registered trademark, and TRACER™ is a trademark, of Voyager Therapeutics, Inc.

Contacts
Investors
[email protected]

Andrew Funderburk
afunderbu[email protected]

Media
Scott Santiamo
[email protected]   

[ Back To TMCnet.com's Homepage ]